Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).

  title={Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).},
  author={Nicholas J. Mercuro and Christina F. Yen and David Shim and Timothy R. Maher and Christopher M McCoy and Peter J Zimetbaum and Howard S. Gold},
  journal={JAMA cardiology},
Importance Administration of hydroxychloroquine with or without azithromycin for the treatment of coronavirus disease 2019 (COVID-19)-associated pneumonia carries increased risk of corrected QT (QTc) prolongation and cardiac arrhythmias. Objective To characterize the risk and degree of QT prolongation in patients with COVID-19 in association with their use of hydroxychloroquine with or without concomitant azithromycin. Design, Setting, and Participants This was a cohort study performed at… 

Figures and Tables from this paper

QT interval evaluation associated with the use of hydroxychloroquine with combined use of azithromycin among hospitalised children positive for coronavirus disease 2019

The experience of QT interval evaluation associated with the use of hydroxychloroquine with concurrent azithromycin among children testing positive for coronavirus disease 2019 did not detect QT prolongation during or at the termination of the treatment in patients.

Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients

Hospitalized patients treated by hydroxychloroquine with or without azithromycin had no significant difference in prolongation of QT interval and outcome, and careful cardiac monitoring during therapy is emphasized, especially in high-risk patients.

QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin

The combination of HY/AZ significantly prolongs the QTc in patients with COVID-19, which may be responsible for life threating arrhythmia in the form of TdP.

Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection

Hydxychloroquine with both ritonavir/darunavir or azithromycin therapy significantly increased the QTc-interval at 7 days, and the risk of developing malignant arrhythmias remained relatively low when these drugs were administered for a limited period of time.

Comparison of hydroxychloroquine plus moxifloxacin versus hydroxychloroquine alone on corrected QT interval prolongation in COVID-19 patients

Patients who received HCQ for the treatment of COVID-19 were at high risk of QTc prolongation, and concurrent treatment with MOX was associated with greater changes in QT c, however, none of patients experienced malignant ventricular arrhythmia or death during treatment.

Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients

A high incidence of extreme QTc interval prolongation among COVID-19 patients on triple combination therapy is observed and the incidence of malignant arrhythmias seems to be not negligible, a careful electrocardiographic monitoring would be advisable.

Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.

Both of hydroxy chloroquine monotherapy and hydroxychloroquine plus azithromycin treatment regimens cause QTc measurement to increase at a statistically significant level, and it is concluded that this increase inQTc did not cause ventricular arrhythmia.

Hydroxychloroquine versus hydroxychloroquine-azithromycin combination therapy on QT interval prolongation of COVID-19 patients: a systematic review and meta-analysis

It was found that there is no significant difference statistically in the QT interval prolongation between HCQ therapy group and HCQ-AZM therapy group.



Azithromycin and the risk of cardiovascular death.

There was a small absolute increase in cardiovascular deaths, which was most pronounced among patients with a high baseline risk of cardiovascular disease and patients in the highest decile of risk for cardiovascular disease.

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.

The preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir.

The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin

The change in the QT interval in 84 adult patients with SARS-CoV-2 infection treated with Hydroxychloroquine/Azithromycin combination prolonged maximally from baseline between days 3 and 4 and in 11% of patients QTc increased to >500 ms, representing high risk group for arrhythmia.

Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients

A risk score using easily obtainable clinical variables predicts patients at highest risk for QTc interval prolongation and may be useful in guiding monitoring and treatment decisions.

[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].

It is found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome.

COVID-19 and Cardiovascular Disease

COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management, and there are a number of promising therapies under active investigation to treat and prevent the disease.

Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

It is recommended that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19, given that the authors could not make a determination whether the benefits outweigh harms for most treatments.